

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number	10594999
Filing Date	2006-09-29
First Named Inventor	Maria Unni Romer et al
Art Unit	1614
Examiner Name	
Attorney Docket Number	59866-000008

## U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20060014224		2006-01-19	Brunner et al.	
	2	20070020707		2007-01-25	Holten-Andersen et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

## NON-PATENT LITERATURE DOCUMENTS

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10594999
Filing Date		2006-09-29
First Named Inventor	Maria Unni Romer et al	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	59866-000008	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A & Engler JA (1993) Matrix metalloproteinases: a review. Crit.Rev.Oral Biol.Med. 4, 197-250.	<input type="checkbox"/>
	2	Cooksley, S. et al., "Immunoassays for the Detection of Human Collagenase, Stromelysin, Tissue Inhibitor of Metalloproteinases (TIMP) and Enzyme-Inhibitor Complexes", Matrix, 10, pp. 285-291, 1990	<input type="checkbox"/>
	3	Stetler-Stevenson WG, Hewitt R & Corcoran M (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin.Cancer Biol. 7, 147-154.	<input type="checkbox"/>
	4	Stetler-Stevenson WG, Kruttsch HC & Liotta LA (1989) Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J.Biol.Chem. 264, 17374-17378.	<input type="checkbox"/>
	5	Stetler-Stevenson WG, Liotta LA & Kleiner Jr DE (1993) Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 7, 1434-1441.	<input type="checkbox"/>
	6	Thorgeirsson UP, Lindsay CK, Cottam DW & Gomez DE (1993) Tumor invasion, proteolysis, and angiogenesis. J. Neurooncol. 18, 89-103.	<input type="checkbox"/>
	7	Welgus HG, Jeffrey JJ, Eisen AZ, Roswit WT & Stricklin GP (1985) Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll.Relat.Res. 5, 167-179.	<input type="checkbox"/>
	8	Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA & Goldberg GI (1989) SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages [published erratum appears in J Biol Chem 1990 Dec 25; 265(36):22570]. J.Biol.Chem. 264, 17213-17221.	<input type="checkbox"/>
	9	Holten-Andersen, MN, et al, 2000, High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, Clinical Cancer Research, vol. 6, No. 11, pp. 4292-4299.	<input type="checkbox"/>
	10	Michael, M, et al, 1999, Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer, Journal of Clinical Oncology, vol. 17, No. 6, pp. 1802-1808. cited by examiner	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10594999
Filing Date	2006-09-29
First Named Inventor	Maria Unni Romer et al
Art Unit	1614
Examiner Name	
Attorney Docket Number	59866-000008

11	Berend, KR, et al, 1998, Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcome, Journal of Bone and Joint Surgery, American Volume, vol. 80:11-17.	<input type="checkbox"/>
12	Arnold, SM, et al, Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in paired primary tumors and brain metastases, Clinical Cancer Research, 1999 Dec;5 (12):4028-33	<input type="checkbox"/>
13	McKay, JA, et al, Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas, International Journal of Oncology, 2000 Jul;17(1):153-8	<input type="checkbox"/>
14	Ikebe, T. et al., Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer, Clinical and Experimental Metastasis, 1994 Jun; 17 (4): 315-23.	<input type="checkbox"/>
15	Khokha, R. et al., "AntisenseRNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells", Science, 243, pp. 947-950, Feb. 17, 1989.	<input type="checkbox"/>
16	Lovgren J., et al., "Measurement of Prostate-Specific Antigen and Human Glandular Kallikrein 2 in Different Body Fluids", J. Androglogy, 20, pp. 348-355, 1999.	<input type="checkbox"/>
17	Remacle, A. et al., "High Levels of TIMP-2 Correlate with Adverse Prognosis in Breast Cancer", Int. J. Cancer, 89, pp. 118-121, 2000.	<input type="checkbox"/>
18	Turan, T. et al., "Free and Total Prostate-Specific Antigen Levels in Saliva and the Comparison with Serum Levels in Men", Eur. Urol., 38 (5), pp. 550-554, 2000.	<input type="checkbox"/>
19	Vignola et al., "Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis", Am. J. Respir. Crit. Care Med., 158, pp. 1945-1950, 1998.	<input type="checkbox"/>
20	Vining, R. and McGinley, R.A., "Hormones in Saliva", Critical Reviews in Clinical Laboratory Science. 1986;23(2): 95-146.	<input type="checkbox"/>
21	McCarthy K. et al., "High Levels of Tissue Inhibitor of Metalloproteinase-1 Predict Poor Outcome in Patients with Breast Cancer", Int. J. Cancer, 1999 Feb 19; 84(1): 44-8	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10594999
Filing Date		2006-09-29
First Named Inventor	Maria Unni Romer et al	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	59866-000008	

22	Leroy et al. (Am. J. Gastroenterol. 2004 Feb; 99 (2): 271-279)	<input type="checkbox"/>
23	Simpson et al. (Colorectal Disease 2000; 2: 100-105)	<input type="checkbox"/>
24	Zweig et al. (Clin Chem. 39 (4); 561-577 (1993)).	<input type="checkbox"/>
25	Jung et al., "Matrix Metalloproteinases 1 and 3, Tissue Inhibitor of Metalloproteinase-1 and the Complex of Metalloproteinase-1/Tissue Inhibitor in Plasma of Patients with Prostate Cancer", Int. J. Cancer (Pred. Oncol.): 74, pp. 220-223 (1997).	<input type="checkbox"/>
26	International Search Report, PCT/DK2003/000634, February 2, 2004	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.